Genetic Signatures shares a similar COVID-19 growth story with other diagnostic companies. GSS’s quarterly revenue jumped 278% yielding a $4.7 million quarter, which has been correlated with the demand for their COVID-19 tests.
Genetic Signatures develops molecular diagnostic tests for bacterial & viral conditions which includes the coronavirus, STDs and norovirus among others. GSS adapted their Easyscreen test to distinguish the Sars-cov-2 from the SARS strand which now yields variants between the two. With this adaptation they are targeting a global expansion for their customer base.
Source: https://geneticsignatures.com/us/wp-content/uploads/sites/3/2089752-GSS-Investor-presentation.pdf